A Phase 3 interventional study of Pertuzumab and Placebo in Metastatic Breast Cancer, sponsored by Genentech, Inc.. Completed at 322 sites in 26 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-12-13.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 104 studies testing pertuzumab in Breast Neoplasms — 26 open to participants now, 45 under way, 7 of them phase 3. pertuzumab · Breast Neoplasms.
Among the 104 studies testing pertuzumab in Breast Neoplasms, this one is the 10th largest by enrollment, is the only one that started in 2008, is one of 23 in phase 3, and was the 3rd registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.
Browse Breast Neoplasms studies →26 of the 104 studies testing pertuzumab in Breast Neoplasms are open now, in 11 countries. Recruiting first, the newest first:
Wen-Ming Cao · Sites in China
Ages 60+ · Women only
Rutgers, The State University of New Jersey · Sites in United States
Ages 18–90
Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18–70 · Women only
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
Alliance for Clinical Trials in Oncology · Sites in United States, Puerto Rico
Ages 18+
By country, each count listing its studies:
pertuzumab: first FDA approval 2012 (PERJETA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, pertuzumab is the treatment under test here. Read study by study →
104 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 63 · Phase 3 23 · Phase 4 3
First in 2003; this study’s year is marked. 1 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 808 is above the median of 72 across 10,903 interventional studies indexed under Breast Neoplasms.
Median enrollment 100 across the 104 interventional studies. Of the 50 that completed or were terminated, 34 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 104 have an industry lead sponsor. The 10 most frequent:
This study is registered under Genentech, Inc., one of the names counted as Hoffmann-La Roche. Under that name alone:
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
229 studies in Breast Neoplasms by Hoffmann-La Roche: 16 open now, 28 under way, 13 of them phase 3. Of 193 finished, 120 (62%) have results posted.
Among the 229 studies in Breast Neoplasms by Hoffmann-La Roche, this one is the 21st largest by enrollment of the 170 interventional ones that give a count, is one of 11 that started in 2008, is one of 61 in phase 3, and was the 33rd registered.
Hoffmann-La Roche’s Breast Neoplasms studies by the year they started, since 1998.
10 of the studies testing pertuzumab in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04784715Phase 3AstraZenecaTrastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | 2027-05-03 |
| NCT05891561Shanghai Jiao Tong University School of MedicineShort-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer | 2026-12 |
| NCT07095023Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNeoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer | 2026-12-30 |
| NCT07187752Shandong Cancer Hospital and InstituteIdentification of HER2-Positive Breast Cancer Molecular Characterization and Subtypes | 2026-12-31 |
| NCT04733118MedSIRChemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer | 2027-03 |
Add all 10 to your calendar (.ics) → With an account.
Among the 104 studies testing pertuzumab in Breast Neoplasms, from their registry updates:
Among Hoffmann-La Roche’s 229 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This study was a Phase III, randomized, double-blind, placebo-controlled, multicenter international clinical trial conducted to investigate the use of pertuzumab in combination with trastuzumab and docetaxel as first-line treatment for participants with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC). Participants could have received one prior hormonal treatment for MBC. Participants may have received systemic breast cancer treatment in the neo-adjuvant or adjuvant setting, provided that the participant had experienced a disease-free interval (DFI) of greater than or equal to (≥)12 months from completion of adjuvant systemic treatment (excluding hormonal therapy) to metastatic diagnosis. Participants may have received trastuzumab and/or a taxane during the neo-adjuvant or adjuvant treatment.
Participants were randomized in 1:1 ratio to receive either pertuzumab or placebo, along with trastuzumab and docetaxel once every 3 weeks (q3w), during the treatment phase of the study until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination. Participants in the Placebo arm were not allowed to receive open-label pertuzumab after discontinuation from study treatment. However, if any analysis of overall survival had met the predefined criteria for statistical significance, participants in the Placebo arm still on treatment were offered the option to receive open-label pertuzumab in addition to other study medications.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to this arm received pertuzumab 420 milligrams (mg) intravenously (IV) once every 3 weeks (q3w) and trastuzumab 6 milligrams per kilogram (mg/kg) IV q3w, plus docetaxel 75 milligrams per square metre of body surface (mg/m\^2) IV q3w (for at least 6 cycles; 1 cycle was 21 days). After Cycle 6, continuation of docetaxel treatment was at the discretion of the participant and treating physician. Participants remained in the treatment phase of the study until investigator-assessed radiographic or clinical evidence of disease progression, unmanageable toxicity, or study termination and were followed for survival until death, loss to follow-up, withdrawal of consent, or study termination.
Drug: Pertuzumab · Drug: Trastuzumab · Drug: Docetaxel
Participants randomized to this arm received placebo IV q3w and trastuzumab 6 mg/kg IV q3w, plus docetaxel 75 mg/m\^2 IV q3w (for at least 6 cycles; 1 cycle was 21 days). After Cycle 6, continuation of docetaxel treatment was at the discretion of the participant and treating physician. Participants remained in the treatment phase of the study until investigator-assessed radiographic or clinical evidence of disease progression, unmanageable toxicity, or study termination and were followed for survival until death, loss to follow-up, withdrawal of consent, or study termination.
Drug: Placebo · Drug: Trastuzumab · Drug: Docetaxel
Pertuzumab was administered as an intravenous (IV) loading dose of 840 milligrams (mg) q3w on Day 1 of Cycle 1 (1 Cycle length = 21 days), and 420 mg q3w on Day 1 of subsequent cycles until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination.
Also known as: Perjeta, RO4368451, RG1273
Placebo (matching pertuzumab) was administered intravenously.
Trastuzumab was administered as an IV loading dose of 8 milligrams per kilogram (mg/kg) q3w on Day 2 of Cycle 1 (1 Cycle length = 21 days), and 6 mg/kg q3w on Day 1 of subsequent cycles until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination.
Also known as: Herceptin
Docetaxel was administered as an IV dose of 75 milligrams per square meter of body surface area (mg/m\^2) q3w on Day 2 of Cycle 1 (1 Cycle length = 21 days), and 75 mg/m\^2 (up to 100 mg/m\^2 as per treating physician discretion) q3w on Day 1 of subsequent cycles until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination. On or prior to Cycle 6, docetaxel was only to be discontinued for progressive disease or unmanageable toxicity. After Cycle 6, continuation of docetaxel treatment was at the discretion of the participant and treating physician.
Also known as: Taxotere
Progression-Free Survival (PFS) Determined by an Independent Review Facility
PFS was defined as the time from randomization to first documented radiographical progressive disease (PD), as determined by an independent review facility (IRF) using RECIST version 1.0, or death from any cause (within 18 weeks of last tumor assessment), whichever occurred first (Kaplan-Meier method). For target lesions, PD was defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum of the LD recorded since treatment started or the appearance of ≥1 new lesion. For non-target lesions, PD was defined as the appearance of ≥1 new lesion or unequivocal progression of existing lesions. Participants without IRF-determined PD or who had not died within 18 weeks of their last IRF-determined, progression-free tumor assessment were censored at the date of the last IRF-reviewed, evaluable tumor assessment; those with no post-baseline tumor assessment and who had not died within 18 weeks of baseline were censored at 1 day.
Time frame: Tumor assessments every 9 weeks from randomization to IRF-determined PD or death from any cause, whichever occurred first, up to the primary completion date (up to 3 years, 3 months)
Overall Survival
Overall survival (OS) was the time from randomization to death from any cause, using Kaplan-Meier methodology. Survival data was collected every 18 weeks during the post-treatment follow-up period until death, loss to follow-up, or withdrawal of consent. Those who were alive, lost to follow up, or withdrew consent were censored at the latest date they participated in the study; those without post-baseline data were censored at 1 day. OS analyses were planned to take place at the primary completion date (First Interim), after 385 deaths (Event-Driven Final), and at the end of study (End-of-Study). A second interim OS analysis was planned due to a formal request from the European Medicines Agency. Median \[range\] time in weeks on study at each OS analysis (Pertuzumab vs. Placebo): First: 77.1 \[0.7-165.3\] vs. 73.1 \[0.4-165.3\]; Second: 117.1 \[0.7-207.9\] vs. 105.9 \[0.4-207.9\]; Event-Driven Final: 189.9 \[0.7-304.1\] vs. 140.5 \[0.4-301.6\]; End-of-Study: 201.8 \[0.7-520.0\] vs. 138.0 \[0.4-514.7\].
Time frame: From randomization to death from any cause, up to each respective analysis data cut-off date (see the Description field for the median time on study per treatment arm)
Progression-Free Survival (PFS) Determined by the Investigator
PFS was defined as the time from randomization to first documented radiographical progressive disease (PD), as determined by the investigator using RECIST version 1.0, or death from any cause (within 18 weeks of last tumor assessment), whichever occurred first (Kaplan-Meier method). For target lesions, PD was defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum of the LD recorded since treatment started or the appearance of ≥1 new lesion. For non-target lesions, PD was defined as the appearance of ≥1 new lesion or unequivocal progression of existing lesions. Participants without PD or who had not died within 18 weeks of their last investigator-determined, progression-free tumor assessment were censored at the date of the last investigator tumor assessment; those with no post-baseline tumor assessment and who had not died within 18 weeks of baseline were censored at 1 day.
Time frame: Tumor assessments every 9 weeks from randomization to investigator-determined PD or death from any cause, whichever occurred first (median [range] time on study in pertuzumab vs. placebo arms: 201.8 [0.7-520.0] weeks vs. 138.0 [0.4-514.7] weeks)
Objective Response Determined by an Independent Review Facility
An objective response was defined as the percentage of participants with confirmed best overall response of complete response (CR) or partial response (PR) determined by an independent review facility (IRF) using RECIST v1.0 on two consecutive occasions ≥4 weeks apart. For target lesions, CR: disappearance of all target lesions; PR: ≥30% decrease in the sum of the longest diameter (LD) of target lesions (baseline sum LD as reference); PD: ≥20% increase in the sum of the LD of target lesions (smallest sum of the LD recorded as reference) or appearance of ≥1 new lesion; SD: neither sufficient shrinkage to qualify for PR nor sufficient increase for PD. For non-target lesions, CR: disappearance of all non-target lesions; Incomplete/SD: persistence of ≥1 non-target lesions; PD: unequivocal progression of existing non-target lesions. 95% confidence intervals (CI) were calculated only for clinical responses using the Pearson-Clopper method.
Time frame: Tumor assessments every 9 weeks from Baseline until IRF-determined progressive disease (PD), death, or first administration of next line of anti-cancer therapy (whichever occurred first), up to the primary completion date (up to 3 years, 3 months)
Duration of Objective Response Determined by an Independent Review Facility
Duration of objective response (estimated using the Kaplan-Meier method) was defined as the time from the initial confirmed complete response (CR) or partial response (PR), the date of tumor assessment at which the CR/PR was first detected by the independent review facility (IRF) using RECIST version 1.0, until the date of IRF-determined progressive disease (PD), death from any cause within 18 weeks of the last tumor assessment, or first administration of next line of anti-cancer therapy (whichever occurred first). If the visit when the initial CR or PR was observed spanned multiple dates, the latest date was used. Only participants in the ITT analysis population with an IRF-determined objective response (CR or PR), observed prior to IRF-assessed PD, death or next line of anti-cancer therapy, were included in the analysis. Participants who did not progress or die after they had a confirmed response were censored at the date of their last IRF-evaluable tumor measurement.
Time frame: From initial IRF-confirmed objective response until IRF-determined progressive disease (PD), death, or first administration of next line of anti-cancer therapy (whichever occurred first), up to the primary completion date (up to 3 years, 3 months)
Time to Symptom Progression
Time to symptom progression was defined as the time from randomization to the first symptom progression as measured by the Functional Assessment of Cancer Therapy-for patients with Breast Cancer (FACT-B) questionnaire with the Trial Outcomes Index-Physical/Functional/Breast (TOI-PFB) subscale. The FACT-B TOI-PFB subscale contains 24 items from 3 subsections of the FACT-B questionnaire: Physical well-being, functional well-being, and additional concerns for breast cancer patients (breast cancer subscale \[BCS\]). All items in the questionnaire were rated by the patient on a 5-point scale ranging from 0 ("not at all") to 4 ("very much"). The total score ranged from 0 to 96. A higher score indicates better perceived quality of life. A positive change score from baseline indicates improvement. Symptom progression was defined as a decrease from baseline of 5 points or more.
Time frame: Every 9 weeks from Baseline until investigator-determined progressive disease, up to the primary completion date (up to 3 years, 3 months)
Overall Number of Participants Who Experienced at Least One Adverse Event, Including Serious and Non-Serious Adverse Events, by Most Severe Intensity (According to NCI-CTCAE v3.0) During the Treatment Period
Adverse event (AE) severity was assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 3.0 (NCI-CTCAE v3.0); if the AE was not specifically listed, the following grades of severity were used: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening or disabling; and Grade 5 = death. Severe and serious are not synonymous. Severity refers to the intensity of an AE, whereas a serious AE must meet criteria set out in the protocol; both were independently assessed for each AE. Only the most severe intensity was counted for multiple occurrences of the same AE in one participant. AEs reported prior to first crossover treatment were included in the Placebo arm, and in the Crossover arm after that date, for participants who crossed over from placebo to pertuzumab. Median \[range\] time on study treatment per arm: Placebo: 49.3 \[0.3-514.7\] weeks; Pertuzumab: 75.7 \[0.6-519.6\] weeks; Crossover: 129.9 \[0.3-322.3\] weeks.
Time frame: Placebo arm: Baseline to last dose of study treatment +42 days (or crossover date); Pertuzumab arm: Baseline to last dose of study treatment +42 days; Crossover arm: Crossover date to last dose of study treatment +42 days (see Description - time per arm)
Overall Number of Adverse Events by Severity (NCI-CTCAE v3.0 All Grades and Grades 3 to 5) Per 100 Patient-Years of Exposure During the Treatment Period
Adverse event (AE) severity, including serious and non-serious AEs, was assessed according to the NCI-CTCAE version 3.0; if the AE was not specifically listed, the following grades of severity were used: Grade 1 is mild; Grade 2 is moderate; Grade 3 is severe; Grade 4 is life-threatening or disabling; and Grade 5 is death. Multiple occurrences of the same AE in 1 participant were counted multiple times. Only AEs that started during the overall study treatment period were included. The cutoff date for inclusion of events and for calculation of patient-years was the date of the most recent follow-up of the participant, defined as the last available date during the treatment period, excluding pre-treatment and safety follow-up data. Confidence intervals were calculated assuming the number of events followed a Poisson distribution. Data reported prior to the date of first crossover treatment were included under the Placebo arm for participants who crossed over from placebo to pertuzumab.
Time frame: From Baseline to 42 days after the last dose of study treatment (total patient-years of exposure on study treatment in Placebo vs. Pertuzumab arms: 526.81 vs. 989.88 patient-years)
Cardiac-Related AEs to Monitor: Number of Participants Who Experienced at Least One Symptomatic Left Ventricular Dysfunction (LVD), Any LVD, or Serious AE Suggestive of Congestive Heart Failure by Severity During the Treatment Period
Cardiac-related adverse events (AEs) to monitor during the study included investigator-assessed symptomatic left ventricular dysfunction (LVD), any LVD, or a serious adverse event (SAE) suggestive of congestive heart failure (CHF). All cardiac-related AEs were graded for severity according to NCI-CTCAE v3.0. Asymptomatic (Grades 1-2) and symptomatic (Grades 3-5) left ventricular systolic dysfunction (LVSD) both coded to the MedDRA preferred term LVD. Investigator-assessed events of symptomatic LVD were also graded for severity of symptoms according to Classes I (least severe) to IV (most severe) of the New York Heart Association (NYHA) Classification. SAEs suggestive of CHF were identified as serious events from the Standardized MedDRA Query (SMQ) (Wide) 'Cardiac Failure'. Median \[range\] time on study treatment per arm: Placebo: 49.3 \[0.3-514.7\] weeks; Pertuzumab: 75.7 \[0.6-519.6\] weeks; Crossover: 129.9 \[0.3-322.3\] weeks.
Time frame: Placebo arm: Baseline to last dose of study treatment +42 days (or crossover date); Pertuzumab arm: Baseline to last dose of study treatment +42 days; Crossover arm: Crossover date to last dose of study treatment +42 days (see Description - time per arm)
Number of Participants Who Experienced at Least One Adverse Event to Monitor (Excluding Cardiac-Related AEs) by Severity During the Treatment Period
The clinical diagnoses listed in this table, excluding cardiac safety (summarized separately), were also selected as adverse events (AEs) to monitor based on clinical and nonclinical data for pertuzumab and the safety profile established for trastuzumab, monoclonal antibodies in general, and potential effects associated with HER receptor inhibition. Search strategies were defined by single or aggregate MedDRA Preferred Terms (PT) through Standardized MedDRA Queries (SMQ), where possible, or based on Roche AE Group Terms (AEGT). Diarrhoea AEs: High-Level Term (HLT) 'Diarrhoea (excl. infective)' and PT 'Diarrhoea infectious'. Leukopenic and Febrile Neutropenic Infections: AEs from 'Infections \& Infestations' with start ≤14 days after start date of Grade ≥3 AEs in SMQ(narrow) 'Leukopenia' or PT 'Febrile neutropenia', respectively. Median \[range\] time on study treatment per arm: Placebo: 49.3 \[0.3-514.7\] weeks; Pertuzumab: 75.7 \[0.6-519.6\] weeks; Crossover: 129.9 \[0.3-322.3\] weeks.
Time frame: Placebo arm: Baseline to last dose of study treatment +42 days (or crossover date); Pertuzumab arm: Baseline to last dose of study treatment +42 days; Crossover arm: Crossover date to last dose of study treatment +42 days (see Description - time per arm)
Overall Number of Participants Who Experienced at Least One Adverse Event Leading to Discontinuation of Any or All Study Medication
Participants could continue study treatment with pertuzumab/placebo plus trastuzumab when docetaxel was discontinued due to an adverse event (AE). Discontinuation of pertuzumab/placebo or trastuzumab due to an AE led to discontinuation of all study medication. The number of participants who discontinued any study medication due to an AE includes those who discontinued all study medication and those who discontinued docetaxel only and then continued on targeted therapy (note: some of these participants may have subsequently discontinued all treatment due to a separate AE). Multiple occurrences of the same adverse event in 1 participant was counted only once. AEs reported prior to first crossover treatment were included in the Placebo arm, and after that date in the Crossover arm, for those who crossed over from placebo to pertuzumab. Median \[range\] time on study treatment per arm: Placebo: 49.3 \[0.3-514.7\] weeks; Pertuzumab: 75.7 \[0.6-519.6\] weeks; Crossover: 129.9 \[0.3-322.3\] weeks.
Time frame: Placebo arm: Baseline to last dose of study treatment +42 days (or crossover date); Pertuzumab arm: Baseline to last dose of study treatment +42 days; Crossover arm: Crossover date to last dose of study treatment +42 days (see Description - time per arm)
Overall Number of Participants Who Experienced at Least One Adverse Event That Resulted in Interruption or Modification of Any Study Medication
Pertuzumab, trastuzumab, and docetaxel administration could have been delayed to assess or treat adverse events (AEs). Docetaxel dose reduction was allowed for myelosuppression, hepatic dysfunction, and other toxicities. No dose reduction was allowed for pertuzumab or trastuzumab. Multiple occurrences of the same adverse event in one participant was counted only once. AEs reported prior to first crossover treatment were included in the Placebo arm, and after that date in the Crossover arm, for participants who crossed over from placebo to pertuzumab. Median \[range\] time on study treatment per arm: Placebo: 49.3 \[0.3-514.7\] weeks; Pertuzumab: 75.7 \[0.6-519.6\] weeks; Crossover: 129.9 \[0.3-322.3\] weeks
Time frame: Placebo arm: Baseline to last dose of study treatment +42 days (or crossover date); Pertuzumab arm: Baseline to last dose of study treatment +42 days; Crossover arm: Crossover date to last dose of study treatment +42 days (see Description - time per arm)
Number of Participants Who Experienced at Least One Adverse Event During the Post-Treatment Follow-Up Period
The post-treatment period was defined as the period following the treatment discontinuation visit. Only the following new adverse events (AEs) should have been reported during the post-treatment follow-up period: 1. Cardiac events (regardless of causality or seriousness) that started up to 1 year after the last dose, except for symptomatic left ventricular systolic dysfunction (regardless of causality) that started up to 3 years after the last dose; and 2. Treatment-related serious AEs, regardless of start date. AEs are listed by Medical Dictionary for Regulatory Activities, Version 21.1 (MedDRA v21.1) System Organ Class (SOC) and Preferred Term (PT); PTs fall under the SOC that is listed immediately above it in the table. Multiple occurrences of the same AE in one participant was counted only once. AEs reported prior to first crossover treatment were included in the Placebo arm, and after that date in the Crossover arm, for participants who crossed over from placebo to pertuzumab.
Time frame: From Day 43 after discontinuation of all study medication to end of post-treatment follow-up period (up to 3 years)
Number of Participants by Categories for the Maximum Absolute Decrease From Baseline in LVEF Value During the Treatment Period
All participants were required to have an left ventricular ejection fraction (LVEF) ≥50% at baseline, as measured by echocardiogram (preferred) or multiple-gated acquisition (MUGA) scan. The same method of LVEF assessment and the same institution/facility used at baseline was used throughout the study, to the extent possible. The baseline value was defined as the last valid value recorded during the pre-treatment period before or on study Day 1. The maximum absolute decrease in LVEF value was defined as the lowest post-baseline value up to the end of the overall study treatment period. Data reported prior to first crossover treatment were included in the Placebo arm, and after that date in the Crossover arm, for participants who crossed over from placebo to pertuzumab. Median \[range\] time on study treatment per arm: Placebo: 49.3 \[0.3-514.7\] weeks; Pertuzumab: 75.7 \[0.6-519.6\] weeks; Crossover: 129.9 \[0.3-322.3\] weeks.
Time frame: Every 9 weeks from the date of randomization until Treatment Discontinuation Visit (see Description for time on study treatment per arm)
Baseline LVEF Value and Change in LVEF From Baseline at Maximum Absolute Decrease Value During the Treatment Period
All participants were required to have a left ventricular ejection fraction (LVEF) ≥50% at baseline, as measured by echocardiogram (preferred) or multiple-gated acquisition (MUGA) scan. The same method of LVEF assessment and the same institution/facility used at baseline was used throughout the study, to the extent possible. The baseline value was defined as the last valid value recorded during the pre-treatment period before or on study Day 1. The maximum absolute decrease in LVEF value was defined as the lowest post-baseline value up to the end of the overall study treatment period. Only data reported prior to the date of first crossover treatment were included for participants who crossed over from placebo to pertuzumab.
Time frame: Every 9 weeks from the date of randomization until Treatment Discontinuation Visit (median [range] time on study treatment per arm: Placebo: 49.3 [0.3-514.7] weeks; Pertuzumab: 75.7 [0.6-519.6] weeks)
Number of Participants With Laboratory Abnormalities in Blood Biochemistry Tests by Highest Grade According to NCI-CTCAE v3.0 During the Treatment Period
Clinical laboratory tests for blood biochemistry parameters were performed at local laboratories; any abnormal values (High or Low) were based on local laboratory normal ranges. Laboratory abnormalities are presented by the highest grade according to NCI-CTCAE v3.0. Not every abnormal laboratory value qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a change in concomitant therapy. Median \[range\] time on study treatment per arm: Placebo: 49.3 \[0.3-514.7\] weeks; Pertuzumab: 75.7 \[0.6-519.6\] weeks; Crossover: 129.9 \[0.3-322.3\] weeks. ALP = alkaline phosphatase; GGT = gamma-glutamyl transferase; SGOT = serum glutamic-oxaloacetic transaminase; SGPT = serum glutamic-pyruvic transaminase
Time frame: On Day 1 of every treatment cycle (1 cycle is 21 days) until Treatment Discontinuation Visit (see Description for time on study treatment per arm)
Number of Participants With Laboratory Abnormalities in Hematology Tests by Highest Grade According to NCI-CTCAE v3.0 During the Treatment Period
Clinical laboratory tests for hematology parameters were performed at local laboratories; any abnormal values (High or Low) were based on local laboratory normal ranges. Laboratory abnormalities are presented by the highest grade according to NCI-CTCAE v3.0. Not every abnormal laboratory value qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a change in concomitant therapy. Median \[range\] time on study treatment per arm: Placebo: 49.3 \[0.3-514.7\] weeks; Pertuzumab: 75.7 \[0.6-519.6\] weeks; Crossover: 129.9 \[0.3-322.3\] weeks. INR = International Normalized Ratio; PTT = partial thromboplastin time; WBC = white blood cell
Time frame: On Day 1 (and Day 8 for some measures) of every treatment cycle (1 cycle is 21 days) until Treatment Discontinuation Visit (see Description for time on study treatment per arm)
| Milestone | Pertuzumab + Trastuzumab + Docetaxel | Placebo + Trastuzumab + Docetaxel |
|---|---|---|
| Started | 402 | 406 |
| Did not receive any study treatment | 2 | 2 |
| Received at least one dose of pertuzumab | 399 | 9 |
| Received at least one dose of placebo | 1 | 395 |
| Crossover from placebo to pertuzumab | 0 | 50 |
| Completed | 119 | 73 |
| Not completed | 283 | 333 |
| Withdrew: Death | 235 | 280 |
| Withdrew: Withdrew consent or lost to follow-up | 48 | 53 |
PFS was defined as the time from randomization to first documented radiographical progressive disease (PD), as determined by an independent review facility (IRF) using RECIST version 1.0, or death from any cause (within 18 weeks of last tumor assessment), whichever occurred first (Kaplan-Meier method). For target lesions, PD was defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum of the LD recorded since treatment started or the appearance of ≥1 new lesion. For non-target lesions, PD was defined as the appearance of ≥1 new lesion or unequivocal progression of existing lesions. Participants without IRF-determined PD or who had not died within 18 weeks of their last IRF-determined, progression-free tumor assessment were censored at the date of the last IRF-reviewed, evaluable tumor assessment; those with no post-baseline tumor assessment and who had not died within 18 weeks of baseline were censored at 1 day.
| Months | Pertuzumab + Trastuzumab + Docetaxel | Placebo + Trastuzumab + Docetaxel |
|---|---|---|
| Progression-Free Survival (PFS) Determined by an Independent Review Facility | 18.5 (15 to 23) | 12.4 (10 to 13) |
Overall survival (OS) was the time from randomization to death from any cause, using Kaplan-Meier methodology. Survival data was collected every 18 weeks during the post-treatment follow-up period until death, loss to follow-up, or withdrawal of consent. Those who were alive, lost to follow up, or withdrew consent were censored at the latest date they participated in the study; those without post-baseline data were censored at 1 day. OS analyses were planned to take place at the primary completion date (First Interim), after 385 deaths (Event-Driven Final), and at the end of study (End-of-Study). A second interim OS analysis was planned due to a formal request from the European Medicines Agency. Median \[range\] time in weeks on study at each OS analysis (Pertuzumab vs. Placebo): First: 77.1 \[0.7-165.3\] vs. 73.1 \[0.4-165.3\]; Second: 117.1 \[0.7-207.9\] vs. 105.9 \[0.4-207.9\]; Event-Driven Final: 189.9 \[0.7-304.1\] vs. 140.5 \[0.4-301.6\]; End-of-Study: 201.8 \[0.7-520.0\] vs. 138.0 \[0.4-514.7\].
| Months | Pertuzumab + Trastuzumab + Docetaxel | Placebo + Trastuzumab + Docetaxel |
|---|---|---|
| End-of-Study OS Analysis | 57.1 (50 to 72) | 40.8 (36 to 48) |
| Event-Driven Final OS Analysis | 56.5 (49 to NA) | 40.8 (36 to 48) |
| Second Interim OS Analysis | NA (42 to NA) | 37.6 (34 to NA) |
| First Interim OS Analysis | NA (NA to NA) | NA (30 to NA) |
PFS was defined as the time from randomization to first documented radiographical progressive disease (PD), as determined by the investigator using RECIST version 1.0, or death from any cause (within 18 weeks of last tumor assessment), whichever occurred first (Kaplan-Meier method). For target lesions, PD was defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum of the LD recorded since treatment started or the appearance of ≥1 new lesion. For non-target lesions, PD was defined as the appearance of ≥1 new lesion or unequivocal progression of existing lesions. Participants without PD or who had not died within 18 weeks of their last investigator-determined, progression-free tumor assessment were censored at the date of the last investigator tumor assessment; those with no post-baseline tumor assessment and who had not died within 18 weeks of baseline were censored at 1 day.
| Months | Pertuzumab + Trastuzumab + Docetaxel | Placebo + Trastuzumab + Docetaxel |
|---|---|---|
| Progression-Free Survival (PFS) Determined by the Investigator | 18.7 (17 to 22) | 12.4 (10 to 14) |
An objective response was defined as the percentage of participants with confirmed best overall response of complete response (CR) or partial response (PR) determined by an independent review facility (IRF) using RECIST v1.0 on two consecutive occasions ≥4 weeks apart. For target lesions, CR: disappearance of all target lesions; PR: ≥30% decrease in the sum of the longest diameter (LD) of target lesions (baseline sum LD as reference); PD: ≥20% increase in the sum of the LD of target lesions (smallest sum of the LD recorded as reference) or appearance of ≥1 new lesion; SD: neither sufficient shrinkage to qualify for PR nor sufficient increase for PD. For non-target lesions, CR: disappearance of all non-target lesions; Incomplete/SD: persistence of ≥1 non-target lesions; PD: unequivocal progression of existing non-target lesions. 95% confidence intervals (CI) were calculated only for clinical responses using the Pearson-Clopper method.
| Percentage of patients | Pertuzumab + Trastuzumab + Docetaxel | Placebo + Trastuzumab + Docetaxel |
|---|---|---|
| Objective Response (CR + PR) | 80.2 (75.6 to 84.3) | 69.3 (64.1 to 74.2) |
| Complete Response (CR) | 5.5 (3.4 to 8.5) | 4.2 (2.3 to 6.9) |
| Partial Response (PR) | 74.6 (69.7 to 79.2) | 65.2 (59.8 to 70.3) |
| Stable Disease (SD) | 14.6 (11.0 to 18.8) | 20.8 (16.6 to 25.6) |
| Progressive Disease (PD) | 3.8 (2.0 to 6.4) | 8.3 (5.6 to 11.8) |
| Unable to Assess (UA) | 0.6 (0.1 to 2.1) | 0.6 (0.1 to 2.1) |
| Missing (No Assessment) | 0.9 (NA to NA) | 0.9 (NA to NA) |
Duration of objective response (estimated using the Kaplan-Meier method) was defined as the time from the initial confirmed complete response (CR) or partial response (PR), the date of tumor assessment at which the CR/PR was first detected by the independent review facility (IRF) using RECIST version 1.0, until the date of IRF-determined progressive disease (PD), death from any cause within 18 weeks of the last tumor assessment, or first administration of next line of anti-cancer therapy (whichever occurred first). If the visit when the initial CR or PR was observed spanned multiple dates, the latest date was used. Only participants in the ITT analysis population with an IRF-determined objective response (CR or PR), observed prior to IRF-assessed PD, death or next line of anti-cancer therapy, were included in the analysis. Participants who did not progress or die after they had a confirmed response were censored at the date of their last IRF-evaluable tumor measurement.
| Weeks | Pertuzumab + Trastuzumab + Docetaxel | Placebo + Trastuzumab + Docetaxel |
|---|---|---|
| Duration of Objective Response Determined by an Independent Review Facility | 87.6 (71 to 106) | 54.1 (46 to 64) |
Time to symptom progression was defined as the time from randomization to the first symptom progression as measured by the Functional Assessment of Cancer Therapy-for patients with Breast Cancer (FACT-B) questionnaire with the Trial Outcomes Index-Physical/Functional/Breast (TOI-PFB) subscale. The FACT-B TOI-PFB subscale contains 24 items from 3 subsections of the FACT-B questionnaire: Physical well-being, functional well-being, and additional concerns for breast cancer patients (breast cancer subscale \[BCS\]). All items in the questionnaire were rated by the patient on a 5-point scale ranging from 0 ("not at all") to 4 ("very much"). The total score ranged from 0 to 96. A higher score indicates better perceived quality of life. A positive change score from baseline indicates improvement. Symptom progression was defined as a decrease from baseline of 5 points or more.
| Weeks | Pertuzumab + Trastuzumab + Docetaxel | Placebo + Trastuzumab + Docetaxel |
|---|---|---|
| Time to Symptom Progression | 18.4 (18 to 27) | 18.3 (18 to 27) |
Adverse event (AE) severity was assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 3.0 (NCI-CTCAE v3.0); if the AE was not specifically listed, the following grades of severity were used: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening or disabling; and Grade 5 = death. Severe and serious are not synonymous. Severity refers to the intensity of an AE, whereas a serious AE must meet criteria set out in the protocol; both were independently assessed for each AE. Only the most severe intensity was counted for multiple occurrences of the same AE in one participant. AEs reported prior to first crossover treatment were included in the Placebo arm, and in the Crossover arm after that date, for participants who crossed over from placebo to pertuzumab. Median \[range\] time on study treatment per arm: Placebo: 49.3 \[0.3-514.7\] weeks; Pertuzumab: 75.7 \[0.6-519.6\] weeks; Crossover: 129.9 \[0.3-322.3\] weeks.
| Participants | Placebo + Trastuzumab + Docetaxel | Pertuzumab + Trastuzumab + Docetaxel | Crossover From Placebo to Pertuzumab |
|---|---|---|---|
| At Least One Serious AE - All Grades | 116 | 160 | 10 |
| At Least One Non-Serious AE - All Grades | 386 | 400 | 45 |
| At Least One AE - All Grades | 391 | 408 | 47 |
| At Least One AE - Grade 1 | 368 | 386 | 44 |
| At Least One AE - Grade 2 | 350 | 383 | 34 |
| At Least One AE - Grade 3 | 229 | 264 | 11 |
| At Least One AE - Grade 4 | 158 | 167 | 1 |
| At Least One AE - Grade 5 | 12 | 8 | 1 |
Adverse event (AE) severity, including serious and non-serious AEs, was assessed according to the NCI-CTCAE version 3.0; if the AE was not specifically listed, the following grades of severity were used: Grade 1 is mild; Grade 2 is moderate; Grade 3 is severe; Grade 4 is life-threatening or disabling; and Grade 5 is death. Multiple occurrences of the same AE in 1 participant were counted multiple times. Only AEs that started during the overall study treatment period were included. The cutoff date for inclusion of events and for calculation of patient-years was the date of the most recent follow-up of the participant, defined as the last available date during the treatment period, excluding pre-treatment and safety follow-up data. Confidence intervals were calculated assuming the number of events followed a Poisson distribution. Data reported prior to the date of first crossover treatment were included under the Placebo arm for participants who crossed over from placebo to pertuzumab.
| Events per 100 patient-years | Placebo + Trastuzumab + Docetaxel | Pertuzumab + Trastuzumab + Docetaxel |
|---|---|---|
| All Grades | 1720.2 (1690.6 to 1750.2) | 1203.0 (1184.9 to 1221.3) |
| Grades 3 to 5 | 225.3 (214.7 to 236.4) | 131.7 (125.8 to 137.9) |
Cardiac-related adverse events (AEs) to monitor during the study included investigator-assessed symptomatic left ventricular dysfunction (LVD), any LVD, or a serious adverse event (SAE) suggestive of congestive heart failure (CHF). All cardiac-related AEs were graded for severity according to NCI-CTCAE v3.0. Asymptomatic (Grades 1-2) and symptomatic (Grades 3-5) left ventricular systolic dysfunction (LVSD) both coded to the MedDRA preferred term LVD. Investigator-assessed events of symptomatic LVD were also graded for severity of symptoms according to Classes I (least severe) to IV (most severe) of the New York Heart Association (NYHA) Classification. SAEs suggestive of CHF were identified as serious events from the Standardized MedDRA Query (SMQ) (Wide) 'Cardiac Failure'. Median \[range\] time on study treatment per arm: Placebo: 49.3 \[0.3-514.7\] weeks; Pertuzumab: 75.7 \[0.6-519.6\] weeks; Crossover: 129.9 \[0.3-322.3\] weeks.
| Participants | Placebo + Trastuzumab + Docetaxel | Pertuzumab + Trastuzumab + Docetaxel | Crossover From Placebo to Pertuzumab |
|---|---|---|---|
| Symptomatic LVD(Investigator)-All NYHA Classes | 7 | 6 | 1 |
| Symptomatic LVD(Investigator)-NYHA Classes III/IV | 4 | 4 | 1 |
| Any LVD - All NCI-CTCAE Grades | 34 | 32 | 3 |
| Any LVD - NCI-CTCAE Grade ≥3 | 13 | 6 | 2 |
| SAE Suggestive of CHF - All NCI-CTCAE Grades | 8 | 8 | 1 |
| SAE Suggestive of CHF - NCI-CTCAE Grade ≥3 | 7 | 7 | 1 |
The clinical diagnoses listed in this table, excluding cardiac safety (summarized separately), were also selected as adverse events (AEs) to monitor based on clinical and nonclinical data for pertuzumab and the safety profile established for trastuzumab, monoclonal antibodies in general, and potential effects associated with HER receptor inhibition. Search strategies were defined by single or aggregate MedDRA Preferred Terms (PT) through Standardized MedDRA Queries (SMQ), where possible, or based on Roche AE Group Terms (AEGT). Diarrhoea AEs: High-Level Term (HLT) 'Diarrhoea (excl. infective)' and PT 'Diarrhoea infectious'. Leukopenic and Febrile Neutropenic Infections: AEs from 'Infections \& Infestations' with start ≤14 days after start date of Grade ≥3 AEs in SMQ(narrow) 'Leukopenia' or PT 'Febrile neutropenia', respectively. Median \[range\] time on study treatment per arm: Placebo: 49.3 \[0.3-514.7\] weeks; Pertuzumab: 75.7 \[0.6-519.6\] weeks; Crossover: 129.9 \[0.3-322.3\] weeks.
| Participants | Placebo + Trastuzumab + Docetaxel | Pertuzumab + Trastuzumab + Docetaxel | Crossover From Placebo to Pertuzumab |
|---|---|---|---|
| Diarrhoea (HLT+PT) - All Grades | 191 | 280 | 25 |
| Diarrhoea (HLT+PT) - Grade ≥3 | 20 | 40 | 1 |
| Rash (AEGT) - All Grades | 155 | 213 | 18 |
| Rash (AEGT) - Grade ≥3 | 6 | 15 | 0 |
| Leukopenia (SMQ-narrow) - All Grades | 231 | 257 | 1 |
| Leukopenia (SMQ-narrow) - Grade ≥3 | 211 | 238 | 0 |
| Leukopenic Infection (PTs) - All Grades | 38 | 53 | 0 |
| Leukopenic Infection (PTs) - Grade ≥3 | 9 | 18 | 0 |
| Febrile Neutropenic Infection (PTs) - All Grades | 3 | 14 | 0 |
| Febrile Neutropenic Infection (PTs) - Grade ≥3 | 1 | 6 | 0 |
| Anaphylaxis and Hypersensitivity (AEGT)-All Grades | 37 | 48 | 1 |
| Anaphylaxis and Hypersensitivity (AEGT)-Grade ≥3 | 10 | 9 | 0 |
| Interstitial Lung Disease (SMQ-narrow) -All Grades | 6 | 10 | 1 |
| Interstitial Lung Disease (SMQ-narrow) -Grade ≥3 | 2 | 3 | 0 |
| QT Prolongation (SMQ-wide) - All Grades | 5 | 16 | 0 |
| QT Prolongation (SMQ-wide) - Grade ≥3 | 1 | 7 | 0 |
| Mucositis (AEGT) - All Grades | 154 | 208 | 12 |
| Mucositis (AEGT) - Grade ≥3 | 8 | 14 | 0 |
| Drug-Related Hepatic Disorder(SMQ-wide)-All Grades | 43 | 47 | 0 |
| Drug-Related Hepatic Disorder (SMQ-wide)-Grade ≥3 | 5 | 8 | 0 |
Participants could continue study treatment with pertuzumab/placebo plus trastuzumab when docetaxel was discontinued due to an adverse event (AE). Discontinuation of pertuzumab/placebo or trastuzumab due to an AE led to discontinuation of all study medication. The number of participants who discontinued any study medication due to an AE includes those who discontinued all study medication and those who discontinued docetaxel only and then continued on targeted therapy (note: some of these participants may have subsequently discontinued all treatment due to a separate AE). Multiple occurrences of the same adverse event in 1 participant was counted only once. AEs reported prior to first crossover treatment were included in the Placebo arm, and after that date in the Crossover arm, for those who crossed over from placebo to pertuzumab. Median \[range\] time on study treatment per arm: Placebo: 49.3 \[0.3-514.7\] weeks; Pertuzumab: 75.7 \[0.6-519.6\] weeks; Crossover: 129.9 \[0.3-322.3\] weeks.
| Participants | Placebo + Trastuzumab + Docetaxel | Pertuzumab + Trastuzumab + Docetaxel | Crossover From Placebo to Pertuzumab |
|---|---|---|---|
| AE Leading to Discontinuation-Any Study Medication | 114 | 131 | 5 |
| AE Leading to Discontinuation-All Study Medication | 24 | 39 | 4 |
Pertuzumab, trastuzumab, and docetaxel administration could have been delayed to assess or treat adverse events (AEs). Docetaxel dose reduction was allowed for myelosuppression, hepatic dysfunction, and other toxicities. No dose reduction was allowed for pertuzumab or trastuzumab. Multiple occurrences of the same adverse event in one participant was counted only once. AEs reported prior to first crossover treatment were included in the Placebo arm, and after that date in the Crossover arm, for participants who crossed over from placebo to pertuzumab. Median \[range\] time on study treatment per arm: Placebo: 49.3 \[0.3-514.7\] weeks; Pertuzumab: 75.7 \[0.6-519.6\] weeks; Crossover: 129.9 \[0.3-322.3\] weeks
| Participants | Placebo + Trastuzumab + Docetaxel | Pertuzumab + Trastuzumab + Docetaxel | Crossover From Placebo to Pertuzumab |
|---|---|---|---|
| Overall Number of Participants Who Experienced at Least One Adverse Event That Resulted in Interruption or Modification of Any Study Medication | 217 | 265 | 16 |
The post-treatment period was defined as the period following the treatment discontinuation visit. Only the following new adverse events (AEs) should have been reported during the post-treatment follow-up period: 1. Cardiac events (regardless of causality or seriousness) that started up to 1 year after the last dose, except for symptomatic left ventricular systolic dysfunction (regardless of causality) that started up to 3 years after the last dose; and 2. Treatment-related serious AEs, regardless of start date. AEs are listed by Medical Dictionary for Regulatory Activities, Version 21.1 (MedDRA v21.1) System Organ Class (SOC) and Preferred Term (PT); PTs fall under the SOC that is listed immediately above it in the table. Multiple occurrences of the same AE in one participant was counted only once. AEs reported prior to first crossover treatment were included in the Placebo arm, and after that date in the Crossover arm, for participants who crossed over from placebo to pertuzumab.
| Participants | Placebo + Trastuzumab + Docetaxel | Pertuzumab + Trastuzumab + Docetaxel | Crossover From Placebo to Pertuzumab |
|---|---|---|---|
| Total with at Least One AE During Post-Treatment | 18 | 17 | 3 |
| Cardiac Disorders (SOC) | 8 | 9 | 1 |
| Left Ventricular Dysfunction (PT) | 6 | 5 | 1 |
| Cardiac Failure (PT) | 0 | 2 | 0 |
| Bundle Branch Block Left (PT) | 0 | 1 | 0 |
| Cardiopulmonary Failure (PT) | 1 | 0 | 0 |
| Myocardial Ischaemia (PT) | 1 | 0 | 0 |
| Pericardial Effusion (PT) | 0 | 1 | 0 |
| Prinzmetal Angina (PT) | 1 | 0 | 0 |
| General Disorders & Admin. Site Conditions (SOC) | 3 | 2 | 0 |
| Oedema Peripheral (PT) | 2 | 1 | 0 |
| Asthenia (PT) | 1 | 0 | 0 |
| Influenza Like Illness (PT) | 0 | 1 | 0 |
| Infections & Infestations (SOC) | 0 | 0 | 2 |
| Influenza (PT) | 0 | 0 | 1 |
| Viral Infection (PT) | 0 | 0 | 1 |
| Abscess Limb (PT) | 0 | 1 | 0 |
| Nasopharyngitis (PT) | 1 | 0 | 0 |
| Subcutaneous Abscess (PT) | 0 | 1 | 0 |
| Musculoskeletal & Connective Tissue Disorders(SOC) | 0 | 0 | 1 |
| Back Pain (PT) | 0 | 0 | 1 |
| Pain in Extremity (PT) | 1 | 0 | 0 |
| Nervous System Disorders (SOC) | 2 | 2 | 0 |
| Neuropathy Peripheral (PT) | 1 | 1 | 0 |
| Cognitive Disorder (PT) | 1 | 0 | 0 |
| Dizziness (PT) | 0 | 1 | 0 |
| Headache (PT) | 0 | 1 | 0 |
| Respiratory, Thoracic & Mediastinal Disorders(SOC) | 2 | 1 | 0 |
| Cough (PT) | 1 | 0 | 0 |
| Dyspnoea (PT) | 1 | 0 | 0 |
| Rhinitis Allergic (PT) | 0 | 1 | 0 |
| Skin & Subcutaneous Tissue Disorders (SOC) | 1 | 2 | 0 |
| Erythema (PT) | 0 | 1 | 0 |
| Nail Disorder (PT) | 1 | 0 | 0 |
| Rash Macular (PT) | 0 | 1 | 0 |
| Blood & Lymphatic System Disorders (SOC) | 1 | 1 | 0 |
| Febrile Neutropenia (PT) | 1 | 0 | 0 |
| Leukopenia (PT) | 0 | 1 | 0 |
| Gastrointestinal Disorders (SOC) | 0 | 2 | 0 |
| Diarrhoea (PT) | 0 | 1 | 0 |
| Stomatitis (PT) | 0 | 1 | 0 |
| Endocrine Disorders (SOC) | 1 | 0 | 0 |
| Thyroid Mass (PT) | 1 | 0 | 0 |
| Eye Disorders (SOC) | 1 | 0 | 0 |
| Retinal Detachment (PT) | 1 | 0 | 0 |
| Immune System Disorders (SOC) | 0 | 1 | 0 |
| Iodine Allergy (PT) | 0 | 1 | 0 |
| Investigations (SOC) | 1 | 0 | 0 |
| Aspartate Aminotransferase Increased (PT) | 1 | 0 | 0 |
| Renal & Urinary Disorders (SOC) | 0 | 1 | 0 |
| Dysuria (PT) | 0 | 1 | 0 |
| Reproductive System & Breast Disorders (SOC) | 0 | 1 | 0 |
| Breast Induration (PT) | 0 | 1 | 0 |
| Vascular Disorders (SOC) | 0 | 1 | 0 |
| Venous Thrombosis (PT) | 0 | 1 | 0 |
All participants were required to have an left ventricular ejection fraction (LVEF) ≥50% at baseline, as measured by echocardiogram (preferred) or multiple-gated acquisition (MUGA) scan. The same method of LVEF assessment and the same institution/facility used at baseline was used throughout the study, to the extent possible. The baseline value was defined as the last valid value recorded during the pre-treatment period before or on study Day 1. The maximum absolute decrease in LVEF value was defined as the lowest post-baseline value up to the end of the overall study treatment period. Data reported prior to first crossover treatment were included in the Placebo arm, and after that date in the Crossover arm, for participants who crossed over from placebo to pertuzumab. Median \[range\] time on study treatment per arm: Placebo: 49.3 \[0.3-514.7\] weeks; Pertuzumab: 75.7 \[0.6-519.6\] weeks; Crossover: 129.9 \[0.3-322.3\] weeks.
| Participants | Placebo + Trastuzumab + Docetaxel | Pertuzumab + Trastuzumab + Docetaxel | Crossover From Placebo to Pertuzumab |
|---|---|---|---|
| LVEF Increase/No Change/Decrease FromBL <10%Points | 252 | 249 | 30 |
| LVEF <50% and Decrease From BL ≥10% to <15% Points | 9 | 7 | 0 |
| LVEF <50% and Decrease From BL ≥15% Points | 19 | 21 | 3 |
| LVEF ≥50% and Decrease From BL ≥10% Points | 95 | 115 | 15 |
| No Baseline (BL) LVEF Value | 3 | 2 | 1 |
All participants were required to have a left ventricular ejection fraction (LVEF) ≥50% at baseline, as measured by echocardiogram (preferred) or multiple-gated acquisition (MUGA) scan. The same method of LVEF assessment and the same institution/facility used at baseline was used throughout the study, to the extent possible. The baseline value was defined as the last valid value recorded during the pre-treatment period before or on study Day 1. The maximum absolute decrease in LVEF value was defined as the lowest post-baseline value up to the end of the overall study treatment period. Only data reported prior to the date of first crossover treatment were included for participants who crossed over from placebo to pertuzumab.
| Percentage points of LVEF | Placebo + Trastuzumab + Docetaxel | Pertuzumab + Trastuzumab + Docetaxel |
|---|---|---|
| Baseline (BL) LVEF Value | 65.6 ± 6.51 | 64.8 ± 6.71 |
| Change in LVEF From BL at Maximum Decrease Value | -7.3 ± 7.15 | -7.5 ± 7.75 |
Clinical laboratory tests for blood biochemistry parameters were performed at local laboratories; any abnormal values (High or Low) were based on local laboratory normal ranges. Laboratory abnormalities are presented by the highest grade according to NCI-CTCAE v3.0. Not every abnormal laboratory value qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a change in concomitant therapy. Median \[range\] time on study treatment per arm: Placebo: 49.3 \[0.3-514.7\] weeks; Pertuzumab: 75.7 \[0.6-519.6\] weeks; Crossover: 129.9 \[0.3-322.3\] weeks. ALP = alkaline phosphatase; GGT = gamma-glutamyl transferase; SGOT = serum glutamic-oxaloacetic transaminase; SGPT = serum glutamic-pyruvic transaminase
| Participants | Placebo + Trastuzumab + Docetaxel | Pertuzumab + Trastuzumab + Docetaxel | Crossover From Placebo to Pertuzumab |
|---|---|---|---|
| Albumin (g/L) - Low, Any Grade (Gr.) | 163 | 196 | 15 |
| Albumin (g/L) - Low, Gr. 1 | 113 | 132 | 10 |
| Albumin (g/L) - Low, Gr. 2 | 46 | 58 | 4 |
| Albumin (g/L) - Low, Gr. 3 | 4 | 6 | 1 |
| Albumin (g/L) - Low, Gr. 4 | 0 | 0 | 0 |
| ALP (U/L) - High, Any Gr. | 184 | 210 | 17 |
| ALP (U/L) - High, Gr. 1 | 158 | 177 | 17 |
| ALP (U/L) - High, Gr. 2 | 19 | 24 | 0 |
| ALP (U/L) - High, Gr. 3 | 7 | 9 | 0 |
| ALP (U/L) - High, Gr. 4 | 0 | 0 | 0 |
| Calcium (mmol/L) - Low, Any Gr. | 156 | 203 | 14 |
| Calcium (mmol/L) - Low, Gr. 1 | 107 | 139 | 11 |
| Calcium (mmol/L) - Low, Gr. 2 | 45 | 49 | 0 |
| Calcium (mmol/L) - Low, Gr. 3 | 3 | 7 | 1 |
| Calcium (mmol/L) - Low, Gr. 4 | 1 | 8 | 2 |
| Calcium (mmol/L) - High, Any Gr. | 54 | 79 | 12 |
| Calcium (mmol/L) - High, Gr. 1 | 50 | 65 | 7 |
| Calcium (mmol/L) - High, Gr. 2 | 0 | 2 | 1 |
| Calcium (mmol/L) - High, Gr. 3 | 3 | 2 | 0 |
| Calcium (mmol/L) - High, Gr. 4 | 1 | 10 | 4 |
| Creatinine (umol/L) - High, Any Gr. | 317 | 346 | 38 |
| Creatinine (umol/L) - High, Gr. 1 | 271 | 279 | 27 |
| Creatinine (umol/L) - High, Gr. 2 | 44 | 54 | 9 |
| Creatinine (umol/L) - High, Gr. 3 | 2 | 6 | 0 |
| Creatinine (umol/L) - High, Gr. 4 | 0 | 7 | 2 |
| Fasting Glucose (mmol/L) - Low, Any Gr. | 42 | 75 | 6 |
| Fasting Glucose (mmol/L) - Low, Gr. 1 | 32 | 61 | 4 |
| Fasting Glucose (mmol/L) - Low, Gr. 2 | 9 | 9 | 0 |
| Fasting Glucose (mmol/L) - Low, Gr. 3 | 1 | 2 | 0 |
| Fasting Glucose (mmol/L) - Low, Gr. 4 | 0 | 3 | 2 |
| Fasting Glucose (mmol/L) - High, Any Gr. | 271 | 299 | 34 |
| Fasting Glucose (mmol/L) - High, Gr. 1 | 168 | 192 | 26 |
| Fasting Glucose (mmol/L) - High, Gr. 2 | 83 | 78 | 8 |
| Fasting Glucose (mmol/L) - High, Gr. 3 | 20 | 26 | 0 |
| Fasting Glucose (mmol/L) - High, Gr. 4 | 0 | 3 | 0 |
| GGT (U/L) - High, Any Gr. | 209 | 225 | 14 |
| GGT (U/L) - High, Gr. 1 | 133 | 144 | 9 |
| GGT (U/L) - High, Gr. 2 | 41 | 52 | 4 |
| GGT (U/L) - High, Gr. 3 | 30 | 27 | 1 |
| GGT (U/L) - High, Gr. 4 | 5 | 2 | 0 |
| Magnesium (mmol/L) - Low, Any Gr. | 79 | 117 | 8 |
| Magnesium (mmol/L) - Low, Gr. 1 | 71 | 98 | 6 |
| Magnesium (mmol/L) - Low, Gr. 2 | 7 | 13 | 0 |
| Magnesium (mmol/L) - Low, Gr. 3 | 1 | 3 | 0 |
| Magnesium (mmol/L) - Low, Gr. 4 | 0 | 3 | 2 |
| Magnesium (mmol/L) - High, Any Gr. | 76 | 105 | 16 |
| Magnesium (mmol/L) - High, Gr. 1 | 58 | 80 | 11 |
| Magnesium (mmol/L) - High, Gr. 2 | 0 | 0 | 0 |
| Magnesium (mmol/L) - High, Gr. 3 | 18 | 22 | 4 |
| Magnesium (mmol/L) - High, Gr. 4 | 0 | 3 | 1 |
| Potassium (mmol/L) - Low, Any Gr. | 80 | 144 | 11 |
| Potassium (mmol/L) - Low, Gr. 1 | 0 | 0 | 0 |
| Potassium (mmol/L) - Low, Gr. 2 | 68 | 118 | 8 |
| Potassium (mmol/L) - Low, Gr. 3 | 10 | 18 | 2 |
| Potassium (mmol/L) - Low, Gr. 4 | 2 | 8 | 1 |
| Potassium (mmol/L) - High, Any Gr. | 67 | 78 | 13 |
| Potassium (mmol/L) - High, Gr. 1 | 49 | 55 | 11 |
| Potassium (mmol/L) - High, Gr. 2 | 15 | 17 | 2 |
| Potassium (mmol/L) - High, Gr. 3 | 3 | 6 | 0 |
| Potassium (mmol/L) - High, Gr. 4 | 0 | 0 | 0 |
| SGOT (U/L) - High, Any Gr. | 184 | 193 | 17 |
| SGOT (U/L) - High, Gr. 1 | 169 | 170 | 15 |
| SGOT (U/L) - High, Gr. 2 | 11 | 12 | 2 |
| SGOT (U/L) - High, Gr. 3 | 4 | 10 | 0 |
| SGOT (U/L) - High, Gr. 4 | 0 | 1 | 0 |
| SGPT (U/L) - High, Any Gr. | 195 | 209 | 19 |
| SGPT (U/L) - High, Gr. 1 | 172 | 175 | 17 |
| SGPT (U/L) - High, Gr. 2 | 18 | 19 | 2 |
| SGPT (U/L) - High, Gr. 3 | 5 | 14 | 0 |
| SGPT (U/L) - High, Gr. 4 | 0 | 1 | 0 |
| Sodium (mmol/L) - Low, Any Gr. | 109 | 135 | 25 |
| Sodium (mmol/L) - Low, Gr. 1 | 87 | 121 | 22 |
| Sodium (mmol/L) - Low, Gr. 2 | 0 | 0 | 0 |
| Sodium (mmol/L) - Low, Gr. 3 | 21 | 12 | 1 |
| Sodium (mmol/L) - Low, Gr. 4 | 1 | 2 | 2 |
| Sodium (mmol/L) - High, Any Gr. | 76 | 103 | 9 |
| Sodium (mmol/L) - High, Gr. 1 | 71 | 91 | 7 |
| Sodium (mmol/L) - High, Gr. 2 | 4 | 9 | 2 |
| Sodium (mmol/L) - High, Gr. 3 | 1 | 2 | 0 |
| Sodium (mmol/L) - High, Gr. 4 | 0 | 1 | 0 |
| Total Bilirubin (umol/L) - High, Any Gr. | 35 | 57 | 7 |
| Total Bilirubin (umol/L) - High, Gr. 1 | 26 | 44 | 6 |
| Total Bilirubin (umol/L) - High, Gr. 2 | 7 | 9 | 0 |
| Total Bilirubin (umol/L) - High, Gr. 3 | 2 | 2 | 0 |
| Total Bilirubin (umol/L) - High, Gr. 4 | 0 | 2 | 1 |
| Uric Acid (umol/L) - High, Any Gr. | 118 | 113 | 15 |
| Uric Acid (umol/L) - High, Gr. 1 | 0 | 0 | 0 |
| Uric Acid (umol/L) - High, Gr. 2 | 0 | 0 | 0 |
| Uric Acid (umol/L) - High, Gr. 3 | 116 | 98 | 10 |
| Uric Acid (umol/L) - High, Gr. 4 | 2 | 15 | 5 |
Clinical laboratory tests for hematology parameters were performed at local laboratories; any abnormal values (High or Low) were based on local laboratory normal ranges. Laboratory abnormalities are presented by the highest grade according to NCI-CTCAE v3.0. Not every abnormal laboratory value qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a change in concomitant therapy. Median \[range\] time on study treatment per arm: Placebo: 49.3 \[0.3-514.7\] weeks; Pertuzumab: 75.7 \[0.6-519.6\] weeks; Crossover: 129.9 \[0.3-322.3\] weeks. INR = International Normalized Ratio; PTT = partial thromboplastin time; WBC = white blood cell
| Participants | Placebo + Trastuzumab + Docetaxel | Pertuzumab + Trastuzumab + Docetaxel | Crossover From Placebo to Pertuzumab |
|---|---|---|---|
| Hemoglobin (g/L) - Low, Any Grade (Gr.) | 350 | 372 | 20 |
| Hemoglobin (g/L) - Low, Gr. 1 | 202 | 186 | 9 |
| Hemoglobin (g/L) - Low, Gr. 2 | 127 | 161 | 6 |
| Hemoglobin (g/L) - Low, Gr. 3 | 21 | 25 | 5 |
| Hemoglobin (g/L) - Low, Gr. 4 | 0 | 0 | 0 |
| Hemoglobin (g/L) - High, Any Gr. | 10 | 23 | 4 |
| Hemoglobin (g/L) - High, Gr. 1 | 9 | 20 | 2 |
| Hemoglobin (g/L) - High, Gr. 2 | 1 | 2 | 0 |
| Hemoglobin (g/L) - High, Gr. 3 | 0 | 1 | 2 |
| Hemoglobin (g/L) - High, Gr. 4 | 0 | 0 | 0 |
| Lymphocytes (10^9/L) - Low, Any Gr. | 259 | 276 | 8 |
| Lymphocytes (10^9/L) - Low, Gr. 1 | 36 | 39 | 0 |
| Lymphocytes (10^9/L) - Low, Gr. 2 | 128 | 136 | 4 |
| Lymphocytes (10^9/L) - Low, Gr. 3 | 64 | 69 | 3 |
| Lymphocytes (10^9/L) - Low, Gr. 4 | 31 | 32 | 1 |
| Lymphocytes (10^9/L)- High, Any Gr. | 58 | 72 | 9 |
| Lymphocytes (10^9/L)- High, Gr. 1 | 0 | 0 | 0 |
| Lymphocytes (10^9/L)- High, Gr. 2 | 49 | 57 | 6 |
| Lymphocytes (10^9/L)- High, Gr. 3 | 9 | 15 | 3 |
| Lymphocytes (10^9/L)- High, Gr. 4 | 0 | 0 | 0 |
| Neutrophils (10^9/L)- Low, Any Gr. | 349 | 371 | 2 |
| Neutrophils (10^9/L)- Low, Gr. 1 | 7 | 4 | 0 |
| Neutrophils (10^9/L)- Low, Gr. 2 | 25 | 34 | 0 |
| Neutrophils (10^9/L)- Low, Gr. 3 | 81 | 99 | 0 |
| Neutrophils (10^9/L)- Low, Gr. 4 | 236 | 234 | 2 |
| PTT (sec) - High, Any Gr. | 6 | 9 | 1 |
| PTT (sec) - High, Gr. 1 | 5 | 2 | 1 |
| PTT (sec) - High, Gr. 2 | 0 | 4 | 0 |
| PTT (sec) - High, Gr. 3 | 1 | 3 | 0 |
| PTT (sec) - High, Gr. 4 | 0 | 0 | 0 |
| Platelets (10^9/L) - Low, Any Gr. | 82 | 92 | 13 |
| Platelets (10^9/L) - Low, Gr. 1 | 75 | 78 | 11 |
| Platelets (10^9/L) - Low, Gr. 2 | 5 | 5 | 0 |
| Platelets (10^9/L) - Low, Gr. 3 | 2 | 3 | 0 |
| Platelets (10^9/L) - Low, Gr. 4 | 0 | 6 | 2 |
| Prothrombin Time (INR) - High, Any Gr. | 135 | 157 | 11 |
| Prothrombin Time (INR) - High, Gr. 1 | 127 | 136 | 9 |
| Prothrombin Time (INR) - High, Gr. 2 | 3 | 6 | 0 |
| Prothrombin Time (INR) - High, Gr. 3 | 5 | 15 | 2 |
| Prothrombin Time (INR) - High, Gr. 4 | 0 | 0 | 0 |
| WBC (10^9/L) - Low, Any Gr. | 366 | 387 | 5 |
| WBC (10^9/L) - Low, Gr. 1 | 36 | 34 | 1 |
| WBC (10^9/L) - Low, Gr. 2 | 92 | 92 | 3 |
| WBC (10^9/L) - Low, Gr. 3 | 186 | 206 | 0 |
| WBC (10^9/L) - Low, Gr. 4 | 52 | 55 | 1 |
| WBC (10^9/L) - High, Any Gr. | 0 | 3 | 1 |
| WBC (10^9/L) - High, Gr. 1 | 0 | 0 | 0 |
| WBC (10^9/L) - High, Gr. 2 | 0 | 0 | 0 |
| WBC (10^9/L) - High, Gr. 3 | 0 | 3 | 1 |
| WBC (10^9/L) - High, Gr. 4 | 0 | 0 | 0 |
Collected over From first treatment dose (12-Feb-2008) through to end of study (23-Nov-2018) for a total safety analysis timeframe of 10 years, 9.5 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo + Trastuzumab + Docetaxel | 261/396 (65.9%) | 116/396 (29.3%) | 386/396 (97.5%) |
| Pertuzumab + Trastuzumab + Docetaxel | 238/408 (58.3%) | 160/408 (39.2%) | 400/408 (98%) |
| Crossover From Placebo to Pertuzumab | 14/50 (28%) | 10/50 (20%) | 45/50 (90%) |
| Event | Placebo + Trastuzumab + Docetaxel | Pertuzumab + Trastuzumab + Docetaxel | Crossover From Placebo to Pertuzumab |
|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 20/396 | 46/408 | 0/50 |
| NeutropeniaBlood and lymphatic system disorders | 19/396 | 18/408 | 0/50 |
| PyrexiaGeneral disorders | 3/396 | 6/408 | 2/50 |
| DiarrhoeaGastrointestinal disorders | 5/396 | 13/408 | 1/50 |
| PneumoniaInfections and infestations | 11/396 | 7/408 | 1/50 |
| CellulitisInfections and infestations | 2/396 | 10/408 | 0/50 |
| AnaemiaBlood and lymphatic system disorders | 3/396 | 3/408 | 1/50 |
| Left ventricular dysfunctionCardiac disorders | 7/396 | 6/408 | 1/50 |
| CataractEye disorders | 0/396 | 2/408 | 1/50 |
| DeathGeneral disorders | 0/396 | 1/408 | 1/50 |
| Event | Placebo + Trastuzumab + Docetaxel | Pertuzumab + Trastuzumab + Docetaxel | Crossover From Placebo to Pertuzumab |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 191/396 | 277/408 | 25/50 |
| AlopeciaSkin and subcutaneous tissue disorders | 240/396 | 248/408 | 4/50 |
| NeutropeniaBlood and lymphatic system disorders | 191/396 | 209/408 | 1/50 |
| NauseaGastrointestinal disorders | 168/396 | 184/408 | 4/50 |
| FatigueGeneral disorders | 148/396 | 156/408 | 5/50 |
| RashSkin and subcutaneous tissue disorders | 96/396 | 156/408 | 11/50 |
| AstheniaGeneral disorders | 122/396 | 114/408 | 3/50 |
| Decreased appetiteMetabolism and nutrition disorders | 106/396 | 120/408 | 2/50 |
| Oedema peripheralGeneral disorders | 111/396 | 102/408 | 1/50 |
| Mucosal inflammationGeneral disorders | 78/396 | 111/408 | 1/50 |
ITT population
| Age, Continuous(years) | Pertuzumab + Trastuzumab + Docetaxel | Placebo + Trastuzumab + Docetaxel | Total |
|---|---|---|---|
| Mean | 53.4 ± 10.94 | 53.5 ± 11.35 | 53.5 ± 11.14 |
| Sex: Female, Male(Participants) | Pertuzumab + Trastuzumab + Docetaxel | Placebo + Trastuzumab + Docetaxel | Total |
|---|---|---|---|
| Female | 402 | 404 | 806 |
| Male | 0 | 2 | 2 |
| Ethnicity (NIH/OMB)(Participants) | Pertuzumab + Trastuzumab + Docetaxel | Placebo + Trastuzumab + Docetaxel | Total |
|---|---|---|---|
| Hispanic or Latino | 39 | 44 | 83 |
| Not Hispanic or Latino | 362 | 362 | 724 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Pertuzumab + Trastuzumab + Docetaxel | Placebo + Trastuzumab + Docetaxel | Total |
|---|---|---|---|
| American Indian or Alaska Native | 3 | 4 | 7 |
| Asian | 128 | 133 | 261 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 10 | 20 | 30 |
| White | 245 | 235 | 480 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 16 | 14 | 30 |
| Region(Participants) | Pertuzumab + Trastuzumab + Docetaxel | Placebo + Trastuzumab + Docetaxel | Total |
|---|---|---|---|
| Asia | 125 | 128 | 253 |
| Europe | 154 | 152 | 306 |
| North America | 67 | 68 | 135 |
| South America | 56 | 58 | 114 |
| Prior Treatment Status(Participants) | Pertuzumab + Trastuzumab + Docetaxel | Placebo + Trastuzumab + Docetaxel | Total |
|---|---|---|---|
| Adjuvant or Neo-Adjuvant Therapy | 184 | 192 | 376 |
| De Novo | 218 | 214 | 432 |
| Independent-Review Facility (IRF)-Determined Disease Status at Screening(Participants) | Pertuzumab + Trastuzumab + Docetaxel | Placebo + Trastuzumab + Docetaxel | Total |
|---|---|---|---|
| Measurable Disease | 343 | 336 | 679 |
| Non-Measurable Disease | 44 | 43 | 87 |
| Not Evaluated | 15 | 27 | 42 |
Showing the first 100 of 322 sites across 26 countries. Choose a country and city above to see the rest.
Ran from Feb 2008 to primary completion in May 2011, 39 months.
Results were first posted in Sep 2012, 1 year 4 months after primary completion.
Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 39 months is close to that.
Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pertuzumab